Javascript must be enabled to continue!
Prevention of Hyperglycemia
View through CrossRef
Hyperglycemia is the elevation of blood glucose concentrations above the normal range. Prolonged uncontrolled hyperglycemia is associated with serious life-threatening complications. Hyperglycemia arises from an imbalance between glucose production and glucose uptake and utilization by peripheral tissues. Disorders that compromise pancreatic function or affect the glucose counter-regulatory hormones cause hyperglycemia. Acute or serious illness or injury may also bring about hyperglycemia, as can many classes of drugs. Metformin lowers blood glucose levels by inhibiting the production of glucose by the liver whilst enhancing uptake of circulating glucose and its utilization in peripheral tissues such as muscle and adipose tissue. Metformin suppresses hepatic gluconeogenesis by inhibiting mitochondrial respiration and causing a reduction of cellular ATP levels. Metformin may also modulate the gut-brain-liver axis, resulting in suppression of hepatic glucose production. Metformin also opposes the hyperglycemic action of glucagon and may ameliorate pancreatic cell dysfunction associated with hyperglycemia. Metformin is therefore recommended for use in the prevention of hyperglycemia, including drug-induced hyperglycemia, in at risk patients. The benefits of metformin in the prevention of hyperglycemia are unmatched despite its contraindications.
Title: Prevention of Hyperglycemia
Description:
Hyperglycemia is the elevation of blood glucose concentrations above the normal range.
Prolonged uncontrolled hyperglycemia is associated with serious life-threatening complications.
Hyperglycemia arises from an imbalance between glucose production and glucose uptake and utilization by peripheral tissues.
Disorders that compromise pancreatic function or affect the glucose counter-regulatory hormones cause hyperglycemia.
Acute or serious illness or injury may also bring about hyperglycemia, as can many classes of drugs.
Metformin lowers blood glucose levels by inhibiting the production of glucose by the liver whilst enhancing uptake of circulating glucose and its utilization in peripheral tissues such as muscle and adipose tissue.
Metformin suppresses hepatic gluconeogenesis by inhibiting mitochondrial respiration and causing a reduction of cellular ATP levels.
Metformin may also modulate the gut-brain-liver axis, resulting in suppression of hepatic glucose production.
Metformin also opposes the hyperglycemic action of glucagon and may ameliorate pancreatic cell dysfunction associated with hyperglycemia.
Metformin is therefore recommended for use in the prevention of hyperglycemia, including drug-induced hyperglycemia, in at risk patients.
The benefits of metformin in the prevention of hyperglycemia are unmatched despite its contraindications.
Related Results
THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
Abstract
Disclosure: M. Hussein: None.
Introduction: Immunotherapy has transformed the treatment landscape of cancer therapy and has created promising...
Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study
Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study
AbstractHyperglycemia is prevalent and closely associated with pulmonary tuberculosis (PTB). This study aimed to investigate the effects of hyperglycemia on the outcomes of PTB tre...
A prospective study: Risk factors and outcomes of hyperglycemia in neonates
A prospective study: Risk factors and outcomes of hyperglycemia in neonates
Background: Hyperglycemia is a significant risk factor for morbidity and mortality among fragile infants who survive the neonatal period, with its risk inversely related to gestati...
Dolutegravir-based antiretroviral therapy-associated hyperglycemia in persons living with human immunodeficiency virus in Niger: a multicentric cross-sectional study
Dolutegravir-based antiretroviral therapy-associated hyperglycemia in persons living with human immunodeficiency virus in Niger: a multicentric cross-sectional study
Background
Growing evidence from clinical and experimental research suggests that dolutegravir is associated with hyperglycemia. This study aimed to determine t...
Postpartum hyperglycemia and associated factors among women attending postnatal clinics in Dar es salaam: a cross-sectional study
Postpartum hyperglycemia and associated factors among women attending postnatal clinics in Dar es salaam: a cross-sectional study
Abstract
Background
The prevalence of Gestational Diabetes Mellitus in Tanzania is raising paralleling its contribution to mate...
Hyperglycemia and its associated factors among people living with HIV on dolutegravir-based antiretroviral therapy in Ethiopia: a cross-sectional study
Hyperglycemia and its associated factors among people living with HIV on dolutegravir-based antiretroviral therapy in Ethiopia: a cross-sectional study
Background:
In many low- and middle-income countries, including Ethiopia, dolutegravir (DTG)-based regimens are the preferred first-line regimens for people liv...
Diabetes Mellitus: Life Style, Obesity and Insulin Resistance
Diabetes Mellitus: Life Style, Obesity and Insulin Resistance
In millennia, 40 million people were died with non-communicable diseases and diabetes is one of them. In diabetes, insulin secretions are not produced properly or resist to body an...
Impact on the Kidney of Pancreas Damage due to Streptozotocin-Induced Hyperglycemia
Impact on the Kidney of Pancreas Damage due to Streptozotocin-Induced Hyperglycemia
Highlights:
This study observed the histology of pancreatic β-cell damage without any intervention to the kidneys of the animal models.
The histological analysis of the kidneys ...

